Kidney Nerve Zapper: Hypertension Device Patent Extended
Published Date: 1/27/2026
Notice
Summary
The FDA has officially set the review period for the Symplicity Spyral Renal Denervation System, a medical device used to treat high blood pressure. This means the company can apply to extend its patent, giving them more time to protect their invention and potentially earn more money. If you want to share your thoughts, you have until March 30, 2026, to send in comments.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Sets 3,161‑Day Review Period
The FDA determined the regulatory review period for the SYMPLICITY SPYRAL RENAL DENERVATION SYSTEM is 3,161 days: 2,801 days in the testing phase and 360 days in the approval phase. That determination lets the patent holder apply to the U.S. Patent and Trademark Office for patent term extension — the applicant seeks 1,491, 1,571, or 1,767 days of extension.
Public Comment and Petition Window
Anyone can submit comments on FDA's determination through https://www.regulations.gov or by mail until 11:59 p.m. Eastern Time on March 30, 2026. Under 21 CFR 60.24 and 21 CFR 60.30, interested persons may ask for a redetermination of the published dates or petition regarding whether the applicant acted with due diligence, and such petitions must be timely and meet the filing requirements described in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in